The disclosure provides a drug composition formulated for inhalation comprisinga conjugate of a surface active agent and a pulmonary active drug. The surfaceactive agent has an affinity for the human alveolar/gas interface and comprisesat least a portion of a mammalian lung surfactant of a mimic thereof. The disclosurealso provides a method of treating a subject suffering from or at risk of sufferingfrom a lung disease comprising administering to the subject a conjugate comprisinga drug for lung treatment and a surface active agent by inhalation in an amounteffective to induce a drug effect in the lungs.
